JW (Cayman) Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
JW (Cayman) Therapeutics has a total shareholder equity of CN¥1.5B and total debt of CN¥333.6M, which brings its debt-to-equity ratio to 22.5%. Its total assets and total liabilities are CN¥2.0B and CN¥497.9M respectively.
Key information
22.5%
Debt to equity ratio
CN¥333.60m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥869.03m |
| Equity | CN¥1.48b |
| Total liabilities | CN¥497.88m |
| Total assets | CN¥1.98b |
Recent financial health updates
No updates
Recent updates
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb
May 10Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
May 03JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?
Feb 03Financial Position Analysis
Short Term Liabilities: 2126's short term assets (CN¥944.4M) exceed its short term liabilities (CN¥323.4M).
Long Term Liabilities: 2126's short term assets (CN¥944.4M) exceed its long term liabilities (CN¥174.5M).
Debt to Equity History and Analysis
Debt Level: 2126 has more cash than its total debt.
Reducing Debt: 2126 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2126 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2126 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.